European Journal of Drug Metabolism and Pharmacokinetics 1989-01-01

Mephenytoin stereoselective elimination in the rat: II. Comparison of mephenytoin stereoselective clearance during chronic intravenous and hepatic portal vein administration.

S H Akrawi, P J Wedlund

Index: Eur. J. Drug Metab. Pharmacokinet. 14(4) , 269-78, (1989)

Full Text: HTML

Abstract

The stereoselective clearances of R- and S-mephenytoin were determined in rats receiving either an intravenous or hepatic portal vein infusion of racemic mephenytoin. The mean +/- SD intravenous clearances of R- and S-mephenytoin were 1630 +/- 250 ml/hr and 630 +/- 250 ml/hr, respectively. The corresponding portal vein clearances for these enantiomers were 2560 +/- 1230 ml/hr (R-mephenytoin) and 540 +/- 230 ml/hr (S-mephenytoin). In spite of the slightly higher clearance for R-mephenytoin following portal vein administration, the difference between the intravenous and portal vein clearances for R- or S-mephenytoin were not found to be significant. Subsequent computer simulations of the data indicated there was less than a 5% probability that this result could be attributed solely to interanimal variability in drug clearance. The estimated extraction ratio of R-mephenytoin by the liver was modest and suggested mephenytoin may undergo a substantial degree of extrahepatic elimination in the rat.


Related Compounds

Related Articles:

Pharmacodynamics of cytochrome P450 2B induction by phenobarbital, 5-ethyl-5-phenylhydantoin, and 5-ethyl-5-phenyloxazolidinedione in the male rat liver or in cultured rat hepatocytes.

1993-01-01

[Chem. Res. Toxicol. 6(2) , 188-96, (1993)]

A markedly diminished pleiotropic response to phenobarbital and structurally-related xenobiotics in Zucker rats in comparison with F344/NCr or DA rats.

1992-03-03

[Biochem. Pharmacol. 43(5) , 1079-87, (1992)]

Active-site characteristics of CYP2C19 and CYP2C9 probed with hydantoin and barbiturate inhibitors.

2004-09-01

[Arch. Biochem. Biophys. 429(1) , 1-15, (2004)]

Electrochemical determination of purine and pyrimidine DNA bases based on the recognition properties of azocalix[4]arene.

2013-04-15

[J. Biochem. Toxicol. 9(5) , 269-78, (1994)]

Biopharmaceutical studies on hydantoin derivatives. V. Pharmacokinetics and pharmacodynamics of 5,5-diphenylhydantoin and 1-benzenesulfonyl-5,5-diphenylhydantoin.

1986-03-01

[J. Pharmacobiodyn. 9(3) , 303-14, (1986)]

More Articles...